Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Morschhauser, F., Flinn, I., Advani, R. H., Diefenbach, C. S., Kolibaba, K., Press, O. W., Sehn, L. H., Chen, A. I., Salles, G., Tilly, H., Cheson, B. D., Assouline, S., Dreyling, M., Hagenbeek, A., Zinzani, P., Yalamanchili, S., Lu, D., Jones, C., Jones, S., Chu, Y., Sharman, J. P. AMER SOC HEMATOLOGY. 2014

View details for Web of Science ID 000349243504136